A Network Pharmacology-Based Study on Active Ingredients of Corydalis Rhizoma on Coronary Heart Disease

Ying Li (lee_monday@163.com)
Shenzhen Hospital of Traditional Chinese Medicine, Guangzhou University of Traditional Chinese Medicine
https://orcid.org/0000-0002-7161-4988

Guhang Wei
Guangzhou University of Chinese Medicine

Zhenkun Zhuang
Guangzhou University of Chinese Medicine

Mingtai Chen
Guangzhou University of Chinese Medicine

Haidan Lin
Guangzhou University of Chinese Medicine

Meihuan Li
Guangzhou University of Chinese Medicine

Yanhui Wu
Guangzhou University of Chinese Medicine

Changjian Yuan
Guangzhou University of Chinese Medicine

Hongyu Chen
Guangzhou University of Chinese Medicine

Zhong Zhang
Guangzhou University of Chinese Medicine

Hong Cheng
Guangzhou University of Chinese Medicine

Research

Keywords: Chinese Traditional Medicine, Corydalis Rhizoma, Network pharmacology, coronary heart disease

DOI: https://doi.org/10.21203/rs.3.rs-41449/v1

License: ☒  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background. Corydalis Rhizoma(CR) showed a high efficacy for coronary heart disease (CHD). However, the interaction between the active ingredients of CR and the targets of CHD has not been unequivocally explained in previous researches. To study the active components and potential targets of Corydalis Rhizoma and to determine the mechanism underlying the exact effect of Corydalis Rhizoma on coronary heart disease, a method of network pharmacology was used.

Materials and Methods. The active components of CR and targets corresponding to each component were scanned out from Traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), and target genes of CHD were searched on GeneCards database and Online Mendelian Inheritance in Man(OMIM) database. The active components and common targets of CR and CHD were used to build the “CR-CHD” network through Cytoscape (version 3.2.1) software as well as protein-protein interaction(PPI) network on String database. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis was executed by clusterProfiler(version 3.8) and DOSE(version 3.6) package on R platform.

Results. 49 active ingredients and 394 relevant targets of CR and the 7173 CHD-related genes were retrieved. 40 common genes were selected for subsequent analysis. Crucial biological processes and pathways were obtained and analyzed, including DNA-binding transcription activator activity, RNA polymerase II-specific, RNA polymerase II transcription factor binding, kinase regulator activity, ubiquitin-like protein ligase binding, uid shear stress and atherosclerosis, TNF signaling pathway, apoptosis, MAPK signaling pathway and PI3K-Akt signaling pathway.

Conclusions. Overall, CR could alleviate CHD through the mechanisms predicted by network pharmacology, laying the foundation for future development of new drugs from traditional Chinese medicine on CHD.

1. Background

Coronary heart disease (CHD) accounts for the greatest proportion of cardiovascular diseases(CVD) which cause over 1.7 million deaths (nearly one-third of all deaths) worldwide, and this figure was expected to grow to 23.6 million by 2030[1]. Despite the positive trend that during the past 25 years, both incidence and mortality (age standardized) have decreased globally, the burden remains disproportionately high in Eastern Europe and Central Asia and age-standardized mortality also remains high in South Asia, North Africa, and the Middle East[2]. Some countries reported increases mortality (particularly those in Eastern Europe and Asia) [3]. Moreover, despite advances in current secondary prevention therapies of CHD, including cholesterol-lowering medications, beta-blockers, calcium antagonists, antiplatelet agents, anticoagulant drugs, these drugs can also triggered some serious side effects like bleeding, muscle pain or weakness, new-onset diabetes.
mellitus[4, 5, 6]. Therefore, there is an urgent need to find more effective and sustainable prevention and treatment strategies for CHD.

Traditional Chinese Medicine (TCM), compared with modern medicine, provides a better long-term curative effect on chronic conditions, as the Danshen dripping pill provides a better long-term curative effect than isosorbide dinitrate does for chronic angina pectoris[7]. Thus, it is necessary to follow up the study and further develop traditional Chinese herbal medicine.

Corydalis Rhizom (CR), recommended in Pharmacopoeia of the People's Republic of China for treatment of chest pain[8], is one of the most commonly prescribed Chinese herbal medicine, according to reviews and data mining of TCM masters (nationally certified in China)'s practice experience, for the treatment of Coronary heart disease[9, 10, 11, 12]. However, the mechanism of the effectiveness of CR on treating Coronary heart disease, since ingredients of CR are complex and their action targets numerous, has not yet been well defined. Therefore, we intend to study the pharmacological mechanism of CR when treating CHD, with the approach of network pharmacology which can provide both complementary support for the development of drug design and better understanding of the mechanisms underlying the actions of traditional Chinese herbal medicine[13, 14, 15]. In present study, we aimed to elucidate the mechanism of CR on treatment of CHD with a comprehensive network pharmacology-based approach. A flowchart of the network pharmacology approach is shown in Figure 1.

2. Materials And Methods

In this study, we constructed an active components of CR-CHD disease targets network which can directly observed the distribution of active components acting on CHD related targets. Moreover, construction of PPI network enabled us to reveal interactions of relative target proteins, by which we got the core genes with calculation. At last, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed for functional annotation of the relative target genes in CR-CHD network.

2.1. Establishment of active components of CR-relative targets database. Traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP, http://tcmspw.com/index.php, last updated on May 31, 2014) was built for herbal medicines, based on systems pharmacology. It contains all the 499 Chinese herbs registered in the Chinese pharmacopoeia with 29,384 ingredients, 3,311 targets and 837 associated diseases[16]. We performed a research on TCMSP with the keyword of “Corydalis Rhizoma” and the screening conditions were drug similarity (DL) greater than 0.18 and oral bioavailability (OB) greater than 30%[17, 18]. The active components of CR-relative targets database was established according to the search result which contained active components of CR and targets corresponding to each component, of which target names were converted into Universal Protein Resource (Uniprot, http://www.uniprot.org/, last updated on November 29, 2019) symbols for subsequent analysis.

2.2. Establishment of disease targets database of CHD. To get a comprehensive collection, the search of disease targets was performed, with the key word of “coronary heart disease”, on GeneCards database (https://www.genecards.org/, Version 4.13) which enables researchers to effectively navigate and
inter-relate a large number of human genes, diseases, variants, proteins, cells, and biological pathways[19] as well as Online Mendelian Inheritance in Man (OMIM, https://omim.org/, last updated on February 5, 2020) which is the primary repository of comprehensive, curated information on genes and genetic phenotypes and the relationships between them[20]. Database of relative gene targets was built with the obtained targets, converted into Uniprot symbols, from both GeneCards and OMIM database.

2.3. Construction of active components of CR-disease targets of CHD network. Intersection between two gene sets of active components of CR-relative targets database and disease targets database of CHD was employed to draw a Venn diagram[21] showing the distribution of these genes. Cytoscape (version 3.2.1) [22] software was used to construct the active components of CR-disease targets of CHD network, with components and targets are represented as “nodes” while associations between them are encoded by “edges”.

2.4. Construction of protein-protein interaction (PPI) network. The String database aims to collect and integrate this information, by consolidating known and predicted protein-protein association data for a large number of organisms[23]. Using the “CR-CHD” common target genes, PPI network[24] was constructed by String database (https://string-db.org/, Version 11.0), with all the targets were only limited the species as “Homo sapiens”, setting combined score ≤ 0.4, from which disconnected nodes were hidden. We calculated the number of adjacent nodes of each node in the PPI network, and drew a histogram.

2.5. GO Enrichment and KEGG Pathway Analysis. In order to understand the biological function of “CR-CHD” common genes, we performed the Gene Ontology (GO, http://geneontology.org/, last updated on January 1, 2020)[25] enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.kegg.jp/, last updated on February 18, 2020)[26] pathway analysis using clusterProfiler(version 3.8) and DOSE(version 3.6) software package on R platform. As increasing quantitative data generated from transcriptomics and proteomics requiring integrative strategies for analysis, clusterProfiler automates the process of biological-term classification and the enrichment analysis of gene clusters[27] while DOSE provides semantic similarity computations among disease ontology (DO) terms, which is important annotation in translating molecular findings from high-throughput data to clinical relevance, and genes which allows biologists to explore the similarities of diseases and of gene functions in disease perspective[28]. Threshold values were set as $P$ value=0.05 and $Q$ value=0.05. A target gene-molecular function and pathway network was built by using Cytoscape (version 3.2.1) software for a more intuitive visualization, with key modules screened from the network by MCODE plugin of Cytoscape (version 3.2.1) [29, 30], setting degree cutoff=2, node score cutoff=0.2, K-score=2, max depth=100.

3. Results

3.1. Active components of CR-relative targets database. A total of 77 reported ingredients of CR were retrieved by searching the TCMSP database, and 49 active ingredients were screened out using OB and DL from ADME parameters. And 394 related targets of the active components were searched from TCMSP. Details of these components are provided in Table 1.

TABLE 1: Active ingredients of CR (OB ≥ 30%, DL ≤ 0.18)
| No | Molecule name                                | OB(%) | DL   | No | Molecule name                          | OB(%) | DL   |
|----|---------------------------------------------|-------|------|----|----------------------------------------|-------|------|
| 1  | bicuculline                                 | 69.67 | 0.88 | 26 | CORYDALINE                             | 65.84 | 0.68 |
| 2  | coptisine                                   | 30.67 | 0.86 | 27 | dehydrocorydaline                      | 41.98 | 0.68 |
| 3  | Dihydrosanguinarine                         | 59.31 | 0.86 | 28 | isocorybulbine                         | 40.18 | 0.66 |
| 4  | sanguinarine                                | 37.81 | 0.86 | 29 | palmatine                              | 64.6  | 0.65 |
| 5  | pseudocoptisine                             | 38.97 | 0.86 | 30 | Hyndarin                               | 73.94 | 0.64 |
| 6  | Tetrahydrocorysamine                        | 34.17 | 0.86 | 31 | Dehydrocorybulbine                     | 46.97 | 0.63 |
| 7  | 18797-79-0                                  | 46.06 | 0.85 | 32 | 13-methyldehydrocorydalmine           | 35.94 | 0.63 |
| 8  | stylopine                                   | 48.25 | 0.85 | 33 | 13-methylpalmatrubine                 | 40.97 | 0.63 |
| 9  | 24240-05-9                                  | 53.75 | 0.83 | 34 | Corynoloxine                           | 38.12 | 0.6  |
| 10 | Fumarine                                    | 59.26 | 0.83 | 35 | Corydalmine                            | 52.5  | 0.59 |
| 11 | Dihydrochelerythrine                        | 32.73 | 0.81 | 36 | Dehydrocorydalmine                    | 43.9  | 0.59 |
| 12 | Cavidine                                    | 35.64 | 0.81 | 37 | Isocorypalmine                         | 35.77 | 0.59 |
| 13 | dehydrocavidine                             | 38.99 | 0.81 | 38 | N-methyllaurotetanine                  | 41.62 | 0.56 |
| 14 | (−)-alpha-N-methylcanadine                  | 45.06 | 0.8  | 39 | norglaucung                            | 30.35 | 0.56 |
| 15 | saulatine                                   | 42.74 | 0.79 | 40 | ST057701                               | 31.87 | 0.56 |
| 16 | berberine                                   | 36.86 | 0.78 | 41 | Corydine                               | 37.16 | 0.55 |
| 17 | (R)-Canadine                                | 55.37 | 0.77 | 42 | (S)-Scoulerine                         | 32.28 | 0.54 |
| 18 | Stigmasterol                                | 43.83 | 0.76 | 43 | Clarkeanidine                          | 86.65 | 0.54 |
| 19 | sitosterol                                  | 36.91 | 0.75 | 44 | demethylcorydalmatine                  | 38.99 | 0.54 |
| 20 | 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolinol[2,1-b]isoquinolin-8-one | 76.77 | 0.73 | 45 | Izoteolin                               | 39.53 | 0.51 |
| 21 | Cryptopin                                   | 78.74 | 0.72 | 46 | methyl-[2-(3,4,6,7-tetramethoxy-1-phenanthryl)ethyl]amine | 61.15 | 0.44 |
| 22 | (1S,8'R)-6,7-dimethoxy-2-methyIspiro[3,4-dihydroisoquinoline-1,7',6,8-dihydrocyclopenta[9]-1,3benzodioxole]-8'-ol | 43.95 | 0.72 | 47 | tetrahydroprotopapaverine              | 57.28 | 0.33 |
| 23 | pontevedrine                                | 30.28 | 0.71 | 48 | quercetin                              | 46.43 | 0.28 |
| 24 | Capaurine                                   | 62.91 | 0.69 | 49 | leonticine                             | 45.79 | 0.26 |
3.2. Disease targets database of CHD. Removing the same genes, a total of 7173 target genes of CHD were screened from GeneCards database and OMIM database. All of these genes were used for construction of disease targets database of CHD.

3.3. Active components of CR-disease targets of CHD network. As shown in Figure 2, we found out that there are 40 "CR-CHD" common target genes, namely target genes with possible roles in treatment of CHD. The common genes correspond to 48 active components of CR. The common genes and the components corresponded to them were converted into a visualized active components of CR-disease targets of CHD network, shown in Figure 3. The distribution of correspondence between ingredients and target genes can be observed intuitively through the network. According to the analysis of the network, distribution of node degree, namely the number of connections or edges the node has to other nodes, of the network is shown in Figure 4. There are 3 components with node degree equal or more than 5, including quercetin, C09367 and stigmasterol, while 3 genes with node degree equal or more than 3, which are PTGS1, CHRM3, AR, of which details are listed in Table 2 and Table 3.

FIGURE 2: Intersection of gene targets of CR and CHD

FIGURE 3: Network of CR active ingredients and CHD disease targets

FIGURE 4: Distribution of node degree of CR active ingredients-CHD disease targets network

TABLE 2: Ingredients with node degree $\geq 10$ in CR active ingredients-CHD disease targets network

| Mol_ID  | Molecule name | Structure | Node degree |
|---------|---------------|-----------|-------------|
| MOL000094 | Quercetin     | ![Quercetin](https://example.com/quercetin.png) | 38          |
| MOL000793 | C09367        | ![C09367](https://example.com/c09367.png) | 6           |
| MOL00449  | Stigmasterol  | ![Stigmasterol](https://example.com/stigmasterol.png) | 5           |
3.4. **Protein-protein interaction network.** As can be seen from Figure 5, the protein-protein interaction of “CR-CHD” common target genes are displayed in the network clearly. Each linkage of target genes represents a meaning, such as protein homology, gene co-expression, inter-genetic adjacency. The more adjacent nodes one node has, the more prominent it is. We can view the key genes with equal or more than 8 adjacent nodes in Figure 6.

**FIGURE 5:** PPI network of CR-CHD shared targets

**FIGURE 6:** Histogram of genes with the number of adjacent genes (≥8) in the PPI network

3.5. **GO enrichment and KEGG pathway analysis of “CR-CHD” common target genes.** A total of 70 biological processes and 67 signaling pathways were obtained through GO enrichment analysis and KEGG pathway analysis with the $P$ value:0.05. The first 20 biological processes were visualized in Figure 7, ranking based on the $P$ values in the order from small to large. Top 5 biological processes which are DNA-binding transcription activator activity, RNA polymerase II-specific with the highest enrichment score, and the next most critical processes, which were RNA polymerase II transcription factor binding, kinase regulator activity, ubiquitin-like protein ligase binding can be used for the subsequent analysis. A total of 12 related signaling pathways, after removing of the extensive pathway of KEGG pathway enrichment by literature search on PubMed and Embase, are shown in Table 4. Fluid shear stress and atherosclerosis signaling pathway with the most abundant gene enrichment can be the significant pathway for further analysis, secondly TNF signaling pathway, apoptosis, MAPK signaling pathway and PI3K-Akt signaling pathway, of which details are visualized in Figure 8. The target gene-molecular function and pathway network was constructed by Cytoscape 3.6.0 software. The network can be seen from Figure 9 that biological processes are represented by small red dots arrayed at the upper part within the circle, while pathways arrayed at the lower part, and dots in the circle indicate genes. Dot size represents a node degree. The bigger the dot is, the more significant the gene is. And the genes with node degree equal or more than 10 in target gene-molecular function and pathway network were listed in Table 5. In addition, the network was analyzed by MCODE plugin, and 3 significant modules were selected as shown in Figure 10.

**FIGURE 7:** Dotplot of the first 20 biological processes with CR-CHD common genes gathering

**TABLE 4:** Pathways related with CHD

| Gene symbol | Node degree |
|-------------|-------------|
| PTGS1       | 42          |
| CHRM3       | 30          |
| AR          | 23          |

**TABLE 3:** Gene with node degree ≥10 in CR active ingredients-CHD disease targets network

| Gene symbol | Node degree |
|-------------|-------------|
| PTGS1       | 42          |
| CHRM3       | 30          |
| AR          | 23          |
| ID      | Term                                                        | Count | Value     |
|---------|-------------------------------------------------------------|-------|-----------|
| hsa05418 | Fluid shear stress and atherosclerosis                      | 10    | 1.35E-07  |
| hsa04668 | TNF signaling pathway                                       | 8     | 2.07E-06  |
| hsa04210 | Apoptosis                                                   | 7     | 8.67E-05  |
| hsa04010 | MAPK signaling pathway                                      | 7     | 2.48E-03  |
| hsa04151 | PI3K-Akt signaling pathway                                  | 7     | 6.30E-03  |
| hsa04115 | p53 signaling pathway                                       | 5     | 2.71E-04  |
| hsa04657 | IL-17 signaling pathway                                     | 5     | 6.31E-04  |
| hsa04064 | NF-kappa B signaling pathway                                | 5     | 8.05E-04  |
| hsa04218 | Cellular senescence                                        | 5     | 4.58E-03  |
| hsa04066 | HIF-1 signaling pathway                                     | 4     | 7.66E-03  |
| hsa04370 | VEGF signaling pathway                                      | 3     | 1.10E-02  |
| hsa04012 | ErbB signaling pathway                                      | 3     | 2.56E-02  |

**FIGURE 8:** Fluid shear stress and atherosclerosis pathway

**FIGURE 9:** Network of target-molecular function-pathway

**FIGURE 10:** Modules of target-molecular function-pathway based on MCODE

**TABLE 5:** Genes with node degree ≥10 in target gene-molecular function and pathway network

| Uniprot symbol | Node degree | Uniprot symbol | Node degree |
|----------------|-------------|----------------|-------------|
| CASP3          | 17          | ERBB3          | 11          |
| PPARG          | 15          | CAP1A1         | 11          |
| NOS3           | 14          | AR             | 10          |
| CASP8          | 13          | AHR            | 10          |
| FOS            | 12          | HIF1A          | 10          |
| GSTP1          | 11          |                |             |

3.6. Active ingredients of CR relative to the hub genes. Based on the above analysis, we listed the hub genes, including AR, FOS, CASP3, IL6, MYC, PPAG, NOS3, CASP8, GSTP1, CYP1A1, AHR, HIF1A, ERBB2, IGF2, HSPB1, CRP, CHRM3, DUOX2, PTGS1, which played important roles in each analysis, and active ingredients corresponding to these genes in Table 6. These hub genes and ingredients are the main focus in this study.

**TABLE 6:** Active ingredients of CR relative to the hub genes
| Gene symbol | Ingredient                                                                 | Analysis                                                                 |
|-------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| AR          | Berberine, coptisine, Dihydrochelerythrine, Dihydrosanguinarine, Corydine,  | PPI network, GO and KEGG enrichment                                        |
|             | Corynoloxine, Dehydrocorbulbine, dehydrocorydaline, Dehydrocorydalmine,     |                                                                          |
|             | 13-methyldehydrocorydalmine, Izoteolin, 13-methylpalmatrubine, N-methylaurot  |                                                                          |
| FOS         | Bicuculline, quercetin                                                      | PPI network, GO and KEGG enrichment                                        |
| CASP3       | Quercetin                                                                  | PPI network, GO and KEGG enrichment                                        |
| IL6         | Quercetin                                                                  | PPI network                                                              |
| MYC         | Quercetin                                                                  | PPI network                                                              |
| PPAG        | Dihydrochelerythrine, Dihydrosanguinarine, Corydalmine, quercetin           | GO and KEGG enrichment                                                    |
| NOS3        | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| CASP8       | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| GSTP1       | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| CYP1A1      | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| AHR         | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| HIF1A       | Quercetin                                                                  | GO and KEGG enrichment                                                    |
| ERBB2       | Quercetin                                                                  | PPI network, MCODE analysis(Cluster 1)                                    |
| IGF2        | Quercetin                                                                  | MCODE analysis(Cluster 1)                                                |
| HSPB1       | Quercetin                                                                  | MCODE analysis(Cluster 1)                                                |
| CRP         | Quercetin                                                                  | MCODE analysis(Cluster 2)                                                |
| CHRM3       | Cryptopin, (S)-Scoulerine, Cavidine, (R)-Canadine, Hyndarin, (-)-alpha-N-    | MCODE                                                                    |
methylcanadine, Capaurine, Clarkeanidine, CORYDALINE, Corydalmine, Corydine, 18797-79-0, dehydrocavidine, demethylcorydalmatine, Izoteolin, isocorybulbine, leonticine, N-methyllaurotetanine, norglaucing, 24240-05-9, saulatine, stylopine, Tetrahydrocorysamine, tetrahydropoprotapaverine, ST057701, Stigmasterol, Fumarine, Isocorypalmine, C09367

| DUOX2    | Quercetin                        | MCODE analysis(Cluster 3) |
|----------|----------------------------------|---------------------------|
| PTGS1    | Berberine, coptisine, Cryptopin, |                           |
|          | Dihydrochelerythrine, Dihydrosauginarine, sanguinarine, (S)-Scoulerine, Cavidine, (R)-Canadine, Hyndarin, Capaurine, Clarkeanidine, Corydalmine, Corydine, 18797-79-0, Corynoloxine, methyl-[2-(3,4,6,7-tetramethoxy-1-phenanthryl)ethyl]amine, dehydrocavidine, Dehydrocorybulbine, dehydrocorydaline, Dehydrocorydalmine, demethylcorydalmatine, 13-methyldehydrocorydalmine, Izoteolin, isocorybulbine, leonticine, 13-methylpalmatrubine, N-methyllaurotetanine, norglaucing, pontevedrine, pseudocoptisine, 24240-05-9, stylopine, Tetrahydrocorysamine, ST057701, 2,3,9,10-tetramethoxy-13-methyl-5,6-dihydroisoquinolino[2,1-b]isoquinolin-8-one, Stigmasterol, palmatine, Fumarine, Isocorypalmine, C09367 |

### 4. Discussion

In this study, we attempted to explore the mechanism of action by which CR treating CHD, with the method of network pharmacology.

In the active components of CR-disease targets of CHD network, quercetin, C09367 and stigmasterol are key ingredients as they are closely related to the most target genes compared to other ingredients of CR. Also, quercetin relates to the majority of hub genes as we concluded in Table 6, while C09367 relates to the rest of hub genes. Quercetin presents significant functions as inhibition of LDL oxidation, reduction of inflammatory markers, endothelium-independent vasodilator effects, protection on endothelial function and nitric oxide, and antiplatelet effect, proved by vitro and some animal models, showing the potential to treat cardiovascular diseases[31, 32, 33]. Also, quercetin showed the analgesic property in various models of inflammation[34]. It is worth mentioning that stigmasterol is related to almost the same genes as C09367, excepting the AR gene. Mouse experiments demonstrated that stigmasterol prevented the HFWD-induced elevation of some di- and triacylglycerol species, decreased serum levels of ceramides, inhibited intestinal absorption of cholesterol and plant sterol, and suppressed hepatic cholesterol[35, 36]. Therefore, these key ingredients can achieve a good effect on CHD by lowering cholesterol, inhibiting platelet aggregation, suppressing inflammatory response and relieving the pain.

After analysis of the active components of CR-disease targets of CHD network, we found out that, PTGS1, CHRM3 and AR are the top three most significant genes, for a total of 40 “CR-CHD” common target genes, with the most relative ingredients of CR. Prostaglandin G/H synthase 1 protein corresponding to PTGS1 gene, is involved in the generation of thromboxane A2 (TXA2), which promotes platelet activation and aggregation, vasoconstriction and proliferation of vascular smooth muscle cells. Therefore, we expect a modulating effect of CR on the expression of PTGS1 encoding the Prostaglandin G/H synthase 1, proving in future experiments. CHRM3 encodes Muscarinic acetylcholine receptor M3 protein proved to cause an endothelium-independent vasodilatation in a mouse experiment[37]. The muscarinic acetylcholine receptor mediates various cellular
responses, including inhibition of adenylate cyclase, breakdown of phosphoinositide and modulation of potassium channels through the action of G proteins[38]. As to AR gene, which encodes androgen receptor protein, is verified in some investigations directly that it has atheroprotective effects through both AR-dependent and AR-independent mechanisms, causing different incidence of cardiovascular disease between men and women[39, 40]. When analyzing the PPI network, genes with the node degree equal or more than 8 were selected as key genes, including CASP3, IL6, MYC, ERBB2, AR, FOS. A member of caspase family, caspase-3, encoded by CASP3 gene, in neuronal cells, has been identified as a key mediator of apoptosis[41]. Encoded by IL6, interleukin-6 is increased in a number of cardiovascular diseases, and also associates with a higher incidence of future cardiovascular events, which effects on activity and expression of endothelial nitric oxide synthase and increases vascular superoxide, thus inactivating NO thereby and limiting NO bioavailability[42]. A Swedish cohort indicated that interleukin-6 trans-signaling driven by the IL6 and soluble IL6 receptor binary complex, could be a promising marker of cardiovascular events risk and possibly be used for anti-inflammatory therapy[43]. Expression of ERBB2 relates to mitochondrial function in cardiomyocytes, according to a mouse experiment[44], encoding receptor tyrosine-protein kinase which has a protective effect on cardiomyocytes[45] as well as regulates outgrowth and stabilization of peripheral microtubules. FOS gene could be one of the indexes reflecting myocardial ischemia[46]. By analyzing the target gene-molecular function and pathway network, there were 11 genes, including CASP3, PPARG, NOS3, CASP8, FOS, GSTP1, ERBB3, CYP1A1, AR, AHR, HIF1A, found out to act important roles in the network, as each of them associating with equal or more than 10 molecular functions and pathways. PPARG might increase the risk of CHD in Asian population, as suggested in a meta-analysis[47], as well as PPARGC161T CT/TT was associated with lower levels of blood TC and LDL-C in Han population[48]. NOS3 is significantly altered in patients with CHD[49], of which expression reduces in patients with atherosclerosis[50]. Caspase-8, encoded by CASP8 gene controls apoptosis, necroptosis and pyroptosis as a switch[51]. CYP1A1 showed an increased expression in females compared to males under the situation of ischemic heart disease[52]. AHR regulates the expression of members in CYP1 family, including CYP1A1 and CYP1A2. It was demonstrated that the AHR system could induce the reporter gene expression by acute hypoxia, of which induction was transient, in an ischemic hind limb model[53]. Hypoxia inducible factors, including HIF1A, are key oxygen sensors that mediate the ability of the cell to deal with hypoxia[54]. Moreover, 3 modules derived from MCODE analysis, which are module 1 consisting of ERBB2, IGF2, HSPB1, module 2 consisting of CHRM3, CRP, and module 3 consisting of DUOX2, PTGS1. IGF2 may be relevant to the regeneration of the mammalian heart after injury[55], of which expression is induced to increase by hypoxia in rat hearts[56]. An experiment suggested that HSPB1 acts a role that reduced inflammation and healed wound after myocardial infarction(MI), expected to be a target for myocardial repair in MI patients[57]. CRP, which is one of the inflammatory biomarkers, is considered to be an indicator for evaluating severity and prognosis of CHD, as lipoproteins inflammation is considered significant in the pathogenesis of CHD[58]. The key genes mentioned above reveal mechanisms underlying the therapeutic effect of CR in the treatment of CHD, participating, to varying degrees, in the process of platelet aggregation, vasoconstriction and vasodilatation, proliferation and repair of vascular endothelial cells and cardiomyocytes, lipid metabolism and in inflammation in the heart. CR may play a full part in the treatment by acting on these key genes. Furthermore, taking these results together, it was concluded that AR, FOS, CASP3 were the 3 most critical genes that played roles in the underlying mechanisms for CR treatment on CHD.
We scanned out the biological process of DNA-binding transcription activator activity, RNA polymerase II-specific with the highest enrichment score, and the next most critical processes, which were RNA polymerase II transcription factor binding, kinase regulator activity, ubiquitin-like protein ligase binding after GO enrichment analysis. GO enrichment analysis showed that CR may achieve effects on CHD through the bidirectional regulation of DNA-binding transcription activator activity, RNA polymerase II-specific, RNA polymerase II transcription factor binding, kinase regulator activity, ubiquitin-like protein ligase binding, though regulation mechanisms still waiting for strong scientific evidence. After KEGG enrichment analysis and removal of wide range of metabolic pathways, we concluded 5 top pathways with the highest enrichment scores, including fluid shear stress and atherosclerosis, TNF signaling pathway, apoptosis, MAPK signaling pathway, PI3K-Akt signaling pathway. Sensing of fluid shear stress and atherosclerosis is considered important in processes of vascular development and remodeling[59, 60]. Studies demonstrated that TNF antagonists has a potent effect of anti-inflammatory and antioxidant[61, 62]. MAPK signaling pathway is activated to regulate apoptosis of cardiac myocytes and angiogenic response of microvascular endothelial cells by related factors, for example, nicotine and protein phosphatase 2A, demonstrating that activation of the MAPK signaling pathway appeared to be a key process in microvascular endothelial cells and cardiac myocytes life-death decisions[63]. The PI3K/Akt signal pathway regulates survival, apoptosis, cell morphology, protein synthesis, and integration of metabolism in cardiomyocytes[64], involved in regulating inflammatory responses, playing a critical role in cardioprotection of preconditioning against ischemia injury[65]. These researches indicate that CR acts on CHD at multiple levels through multiple biological processes and mainstream signaling pathways, mainly regulating vascular development and remodeling, inflammatory process, oxidation, endothelial cell and cardiacmyocyte apoptosis and protein synthesis. Furthermore, we can understand the advantages of CR in the treatment of CHD and its potential in new drug development by this study.

5. Conclusions

Traditional Chinese medicine itself with diversified structures have multi-targets and multi-pathways effect, thus increasing the difficulty to identify mechanisms of active ingredients in CR acting on CHD. Network pharmacology offers a promising new way to solve this problem, basing on the network of “drug-target-disease-pathway” interactions and bioinformatics analysis. Combined with results of above analyses, it suggests that quercetin plays a dominant role in therapy of CR on CHD, as it relates to the most target genes of CHD. And also, some of these genes corresponding to quercetin are demonstrated to take a critical part in the subsequent PPI network, GO and KEGG enrichment analyses. Among them are FOS and CASP3, which involve in fluid shear stress and atherosclerosis, TNF signaling pathway. The next significant ingredients are C09367 and stigmasterol, for their common target genes involve in the control of the same biological processes, for example, DUOX2 and PTGS1 participant in heme binding and tetrapyrrole binding, CHRM3 and CRP involve in neurotransmitter binding and ammonium ion binding. Moreover, the AR gene, related to C09367, is the key player in PPI network, GO and KEGG enrichment. In this study, we analyzed the active components of CR as well as the possible mechanisms of these components on CHD, forming the basis of a future research projects.

Abbreviations
Declarations

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Ying Li and Zhenkun Zhuang searched articles in electronic databases and wrote the manuscript. Mingtai Chen, Haidan Lin and Changjian Yuan analyzed the data. Meihuan Li and Yanhui Wu performed the data extraction. Zhong Zhang designed the study and amended the paper.

Acknowledgments
This study was supported by the SanMing Project of Shenzhen City of China (grant number: SZSM201612033).

**Supplementary Materials**

Supplementary Table 1: Ingredients and related genes of CR. Supplementary Table 2: Genes of CHD. Supplementary Table 3: Common genes of CR and CHD. Supplementary Table 4: Biological processes and pathways from KEGG and GO. *(Supplementary Materials)*

**Author details**

1 Shenzhen Hospital of Traditional Chinese Medicine/Forth College of Clinical Medicine, Guangzhou University of Traditional Chinese Medicine, Shenzhen, 518000, China. 2 Shenzhen Hospital of Guangzhou University of Traditional Chinese Medicine (Futian), Shenzhen, 518000, China. 3 Yantian Hospital, Shenzhen, 518000, China.

**References**

1. N. D. Wong, "Epidemiological studies of CHD and the evolution of preventive cardiology", *Nature reviews. Cardiology*, vol.11, no.5, pp. 276–289, 2014.
2. Joseph P, Leong D, McKee M, et al., "Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors", *Circulation research*, vol.121, no.6, pp. 677–694, 2017.
3. Herrington W, Lacey B, Sherliker P, et al., "Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease", *Circulation research*, vol.118, no.4, pp. 535–546, 2016.
4. Valgimigli M, Bueno H, Byrne RA, et al., "2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)", *European heart journal*, vol.39, no.3, pp. 213–260, 2018.
5. Smith SC Jr, Benjamin EJ, Bonow RO, et al., "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation", *Circulation*, vol.124, no.22, pp. 2458–2473, 2011.
6. Collins R, Reith C, Emberson J, et al., "Interpretation of the evidence for the efficacy and safety of statin therapy", *Lancet (London, England)*, vol.388, no.10059, pp. 2532–2561, 2016.
7. P. Tian, "Convergence: Where West meets East", *Nature*, vol.480, no.7378, pp. S84-S86, 2011.
8. Committee CP, *Chinese Pharmacopoeia*, China medical science and technology press, Beijing, China, 2015.
9. Yuerong Jiang Y, Xie J, Zhang, et al., "CHEN Keji's Medication Laws for Treating Blood Stasis Pattern of Cardiovascular Diseases: A Data Mining Research", *Journal of Traditional Chinese Medicine*, vol.56, no.05, pp. 376–380, 2015.
10. Ren Y, Chen Z, Zhang M, et al., "Cluster Analysis of Medication Laws for Treating Coronary Heart Disease by Distinguished Veteran Doctors of Traditional Chinese Medicine", *Chinese Journal of Integrated Traditional and Western Medicine*, vol.36, no.04, pp. 411–414, 2016.
11. Wei J, Zhang X, Chuanhua Yang, "Discussion about professor ZHANG Wen-gao in the treatment of angina cordis of coronary heart disease with the formula of invigorating qi, warming yang and promoting blood circulation", *China Journal of Traditional Chinese Medicine and Pharmacy*, vol. 30, no. 02, pp. 443–445, 2015.

12. Wei Xie L, Kang S, Wang, et al., "Experience of ZHANG Li-bo in the treatment of coronary heart disease", *Journal of Traditional Chinese Medicine*, vol. 52, no. 18, pp. 1539–1541, 2011.

13. Li S, B. Zhang, "Traditional Chinese medicine network pharmacology: theory, methodology and application", *Chinese journal of natural medicines*, vol. 11, no. 2, pp. 110–120, 2013.

14. Hao DC, P. G. Xiao, "Network pharmacology: a Rosetta Stone for traditional Chinese medicine", *Drug development research*, vol. 75, no. 5, pp. 299–312, 2014.

15. Boezio B, Audouze K, Ducrot P, et al., "Network-based Approaches in Pharmacology", *Molecular informatics*, vol. 36, no. 10, pp. 10.1002/minf.201700048, 2017.

16. Ru J, Li P, Wang J, et al., "TCMSP: a database of systems pharmacology for drug discovery from herbal medicines". J Cheminform. 2014;6:13–3.

17. Gan D, Xu X, Chen D, et al., "Network Pharmacology-Based Pharmacological Mechanism of the Chinese Medicine Rhizoma drynariae Against Osteoporosis". Medical science monitor: international medical journal of experimental clinical research. 2019;25:5700–16.

18. Yu G, Wang W, Wang X, et al., "Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis" *BMC complementary and alternative medicine*, vol. 18, no. 1, pp. 292–292, 2018.

19. Stelzer G, Rosen N, Plaschkes I, et al., "The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses", *Current protocols in bioinformatics*, vol. 54, pp. 1.30.31–31.30.33, 2016.

20. Amberger JS, A. Hamosh, "Searching Online Mendelian Inheritance in Man (OMIM): A Knowledgebase of Human Genes and Genetic Phenotypes", *Current protocols in bioinformatics*, vol. 58, pp. 1.2.1–1.2.12, 2017.

21. Hur B, Kang D, Lee S, et al., "Venn-diaNet: venn diagram based network propagation analysis framework for comparing multiple biological experiments", *BMC bioinformatics*, vol. 20, no. Suppl 23, pp. 667–667, 2019.

22. Su G, Morris JH, Demchak B, et al., "Biological network exploration with Cytoscape 3", *Current protocols in bioinformatics*, vol. 47, pp. 8.13.11–18.13.24, 2014.

23. Szklarczyk D, Morris JH, Cook H, et al., "The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible", *Nucleic acids research*, vol. 45, no. D1, pp. D362-D368, 2017.

24. Athanasios A, Charalampos V, Vasileios T, et al., "Protein-Protein Interaction (PPI) Network: Recent Advances in Drug Discovery", *Current drug metabolism*, vol. 18, no. 1, pp. 5–10, 2017.

25. Mi H, Muruganujan A, Ebert D, et al., "PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools", *Nucleic acids research*, vol. 47, no. D1, pp. D419-D426, 2019.

26. M. Kanehisa, "Toward understanding the origin and evolution of cellular organisms", *Protein science: a publication of the Protein Society*, vol. 28, no. 11, pp. 1947–1951, 2019.

27. Yu G, Wang L-G, Han Y, et al., "clusterProfiler: an R package for comparing biological themes among gene clusters". Omics: a journal of integrative biology. 2012;16: no. 5, pp. 284–7.
28. Yu G, Wang L-G, Yan G-R, et al., "DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis", *Bioinformatics (Oxford, England)*, vol.31, no.4, pp. 608–609, 2015.

29. Cao L, Chen Y, Zhang M, et al., "Identification of hub genes and potential molecular mechanisms in gastric cancer by integrated bioinformatics analysis", *PeerJ*, vol.6, pp.e5180-e5180, 2018.

30. Feng H, Gu Z-Y, Li Q, et al., "Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis", *Journal of ovarian research*, vol.12, no.1, pp. 35–35, 2019.

31. Li Y, Yao J, Han C, et al., "Quercetin, Inflammation and Immunity", *Nutrients*, vol.8, no.3, pp. 167–167, 2016.

32. Patel RV, Mistry BM, Shinde SK, et al., "Therapeutic potential of quercetin as a cardiovascular agent". Eur J Med Chem. 2018;155:889–904.

33. Oh WJ, Endale M, Park S-C, et al., "Dual Roles of Quercetin in Platelets: Phosphoinositide-3-Kinase and MAP Kinases Inhibition, and cAMP-Dependent Vasodilator-Stimulated Phosphoprotein Stimulation", *Evidence-based complementary and alternative medicine: eCAM*, vol.2012, pp. 485262–485262, 2012.

34. Carullo G, Cappello AR, Frattaruolo L, et al., "Quercetin and derivatives: useful tools in inflammation and pain management", *Future medicinal chemistry*, vol.9, no.1, pp. 79–93, 2017.

35. Feng S, Dai Z, Liu AB, et al., "Intake of stigmasterol and β-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet", *Biochimica et biophysica acta. Molecular and cell biology of lipids*, vol.1863, no.10, pp. 1274–1284, 2018.

36. Batta AK, Xu G, Honda A, et al., "Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat" *Metabolism: clinical and experimental*, vol.55, no.3, pp. 292–299, 2006.

37. Tangsucharit P, Takatori S, Zamami Y, et al., "Muscarinic acetylcholine receptor M1 and M3 subtypes mediate acetylcholine-induced endothelium-independent vasodilatation in rat mesenteric arteries". J Pharmacol Sci. 2016;130:24–32. no.1.

38. Yang J, Williams JA, Yule DI, et al., "Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization", *Molecular pharmacology*, vol.48, no.3, pp. 477–485, 1995.

39. Boese AC, Kim SC, Yin K-J, et al., "Sex differences in vascular physiology and pathophysiology: estrogen and androgen signaling in health and disease", *American journal of physiology. Heart and circulatory physiology*, vol.313, no.3, pp.H524-H545, 2017.

40. Huang C-K, Lee SO, Chang E, et al., "Androgen receptor (AR) in cardiovascular diseases", *The Journal of endocrinology*, vol.229, no.1, pp.R1-R16, 2016.

41. D’Amelio M, Cavallucci V. F. Ceconii, "Neuronal caspase-3 signaling: not only cell death". Cell death differentiation. 2010;17:1104–14. no.7.

42. S. P. Didion,"Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature", *International journal of molecular sciences*, vol.18, no.12, pp. 2563, 2017.

43. Ziegler L, Gajulapuri A, Frumento P, et al., "Interleukin 6 trans-signalling and risk of future cardiovascular events", *Cardiovascular research*, vol.115, no.1, pp. 213–221, 2019.
44. Grazette LP, Boecker W, Matsui T, et al.,”Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy”, Journal of the American College of Cardiology, vol.44, no.11, pp. 2231–2238, 2004.

45. Spector NL, Yarden Y, Smith B, et al.,”Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells”, Proceedings of the National Academy of Sciences of the United States of America, vol.104, no.25, pp. 10607–10612, 2007.

46. Xu Y-C, Jing X-L, Ke Y, et al.,”Expression of brain natriuretic peptide and c-fos gene in rat after acute myocardial ischemia and its medicolegal significance”, Fa yi xue za zhi, vol.24, no.1, pp. 1–4, 2008.

47. González-Castro TB, Tovilla-Zárate CA, Juárez-Rojop IE, et al.,”PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease”, Biomarkers in medicine, vol.12, no.3, pp. 287–297, 2018.

48. Wei W-M, Wu X-Y, Li S-T, et al.,”PPARG gene C161T CT/TT associated with lower blood lipid levels and ischemic stroke from large-artery atherosclerosis in a Han population in Guangdong”, Neurological research, vol.38, no.7, pp. 620–624, 2016.

49. V A, Nayar PG, Murugesan R, et al.,”A systems biology and proteomics-based approach identifies SRC and VEGFA as biomarkers in risk factor mediated coronary heart disease”, Molecular bioSystems, vol.12, no.3, pp. 287–297, 2018.

50. Chen X, Niroomand F, Liu Z, et al.,”Expression of nitric oxide related enzymes in coronary heart disease”, Basic research in cardiology, vol.101, no.4, pp. 346–353, 2006.

51. Fritsch M, Günther SD, Schwarzer R, et al.,”Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis”, Nature, vol.575, no.7784, pp. 683–687, 2019.

52. Stone G, Choi A, Meritxell O, et al.,”Sex differences in gene expression in response to ischemia in the human left ventricular myocardium”, Human molecular genetics, vol.28, no.10, pp. 1682–1693, 2019.

53. Cilek MZ, Hirohata S, Faruk Hatipoglu O, et al.,”AHR, a novel acute hypoxia-response sequence, drives reporter gene expression under hypoxia in vitro and in vivo”. Cell Biol Int. 2011;35:1–8. no.1.

54. Kumar H, D.-K. Choi,”Hypoxia Inducible Factor Pathway and Physiological Adaptation: A Cell Survival Pathway?”, Mediators of inflammation, vol.2015, pp. 584758–584758, 2015.

55. Wang K, Shen H, Gan P, et al.,”Differential roles of insulin like growth factor 1 receptor and insulin receptor during embryonic heart development”, BMC developmental biology, vol.19, no.1, pp. 5–5, 2019.

56. Hwang J-M, Weng Y-J, Lin JA, et al.,”Hypoxia-induced compensatory effect as related to Shh and HIF-1alpha in ischemia embryo rat heart”, Molecular and cellular biochemistry, vol.311, no.1–2, pp. 179–187, 2008.

57. Wang Y, Liu J, Kong Q, et al.,”Cardiomyocyte-specific deficiency of HSPB1 worsens cardiac dysfunction by activating NFkB-mediated leucocyte recruitment after myocardial infarction”, Cardiovascular research, vol.115, no.1, pp. 154–167, 2019.

58. Li H, Sun K, Zhao R, et al.,”Inflammatory biomarkers of coronary heart disease”, Frontiers in bioscience (Scholar edition), vol.10, pp. 185–196, 2018.

59. Baeyens N, Bandyopadhyay C, Coon BG, et al.,”Endothelial fluid shear stress sensing in vascular health and disease”, The Journal of clinical investigation, vol.126, no.3, pp. 821–828, 2016.
60. N. Baeyens, "Fluid shear stress sensing in vascular homeostasis and remodeling: Towards the development of innovative pharmacological approaches to treat vascular dysfunction", *Biochemical pharmacology*, vol. 158, pp. 185–191, 2018.

61. Amini-Shirazi N, Hoseini A, Ranjbar A, et al., "Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice", *Toxicology mechanisms and methods*, vol. 19, no. 2, pp. 183–189, 2009.

62. Kageyama Y, Takahashi M, Ichikawa T, et al., "Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis", *Clinical and experimental rheumatology*, vol. 26, no. 1, pp. 73–80, 2008.

63. Sun Y, Liu W-Z, Liu T, et al., "Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis". J Recept Signal Transduct Res. 2015;35:600–4. no. 6.

64. Damilano F, Perino A. E. Hirsch, "PI3K kinase and scaffold functions in heart". Ann N Y Acad Sci. 2010;1188:39–45.

65. Hu X, Xu C, Zhou X, et al., "PI3K/Akt signaling pathway involved in cardioprotection of preconditioning with high mobility group box 1 protein during myocardial ischemia and reperfusion", *International journal of cardiology*, vol. 150, no. 2, pp. 222–223, 2011.

**Figures**
Figure 1
Flow chart of the research
Figure 2

Intersection of gene targets of CR and CHD
Figure 3

Network of CR active ingredients and CHD disease targets
Figure 4

Distribution of node degree of CR active ingredients-CHD disease targets network
**Figure 5**

PPI network of CR-CHD shared targets
Figure 6

Histogram of genes with the number of adjacent genes (≥8) in the PPI network
Figure 7

Dotplot of the first 20 biological processes with CR-CHD common genes gathering
Figure 8

Fluid shear stress and atherosclerosis pathway
Figure 9

Network of target-molecular function-pathway

Figure 10

Modules of target-molecular function-pathway based on MCODE
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementary4.xlsx
- Supplementary3.xlsx
- Supplementary2.xlsx
- Supplementary1.xlsx